Adamas Pharmaceuticals, Inc. (ADMS) Given Average Rating of “Buy” by Brokerages
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has been assigned an average recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $39.50.
A number of analysts have recently issued reports on ADMS shares. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, September 1st. They noted that the move was a valuation call. BidaskClub cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Adamas Pharmaceuticals in a research report on Sunday, September 17th. Finally, Cowen and Company set a $45.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th.
Adamas Pharmaceuticals (ADMS) traded down 4.38% during mid-day trading on Wednesday, hitting $20.74. 926,752 shares of the stock were exchanged. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $24.18. The company has a 50-day moving average price of $20.71 and a 200-day moving average price of $17.68. The company’s market cap is $466.94 million.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period in the previous year, the business posted ($0.78) EPS. The firm’s revenue was down 90.9% on a year-over-year basis. On average, analysts predict that Adamas Pharmaceuticals will post ($3.77) earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADMS. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals in the second quarter valued at $109,000. American International Group Inc. grew its position in Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after acquiring an additional 682 shares during the period. Virtu KCG Holdings LLC bought a new stake in Adamas Pharmaceuticals in the second quarter valued at $184,000. Wells Fargo & Company MN grew its position in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after acquiring an additional 3,358 shares during the period. Finally, Alps Advisors Inc. grew its position in Adamas Pharmaceuticals by 6.7% in the second quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock valued at $353,000 after acquiring an additional 1,272 shares during the period. Institutional investors and hedge funds own 69.16% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.